Patient Resources & Information for IMBRUVICA® (ibrutinib)
What is IMBRUVICA® (ibrutinib)? IMBRUVICA® (ibrutinib) is a prescription medicine used to treat adults with: Mantle cell lymphoma (MCL) who have received at least one prior treatment; Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion…
HCP Information for Once-Daily IMBRUVICA® (ibrutinib) HCP
IMBRUVICA® (ibrutinib) is a kinase inhibitor indicated for the treatment of adult patients with: Mantle cell lymphoma (MCL) who have received at least one prior therapy. Accelerated approval was granted for this indication based on overall response rate.…
Imbruvica Prices, Coupons & Patient Assistance Programs ...
Imbruvica Prices, Coupons and Patient Assistance Programs. Imbruvica (ibrutinib) is a member of the BTK inhibitors drug class and is commonly used for Chronic Lymphocytic Leukemia, Graft-versus-host disease, Lymphoma, and others.6/10…
Contact Us IMBRUVICA® (ibrutinib)
Find contact information for IMBRUVICA®. Diarrhea is a common side effect in people who take IMBRUVICA®. Drink plenty of fluids during treatment with IMBRUVICA® to help reduce your risk of losing too much fluid (dehydration) due to diarrhea.…
Ibrutinib Uses, Side Effects & Warnings - Drugs.com
Dec 03, 2019 · Ibrutinib is used to treat mantle cell lymphoma, marginal zone lymphoma, Waldenstrom's macroglobulinemia, chronic lymphocytic leukemia, and small lymphocytic lymphoma.. Ibrutinib is also used to treat chronic graft-versus-host disease. Ibrutinib is usually given after …6.4/10…
Ibrutinib Medicare Coverage and Co-Pay Details - GoodRx
IBRUTINIB is a medicine that targets proteins in cancer cells and stops the cancer cells from growing. It is used to treat mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, marginal zone lymphoma, Waldenstrom macroglobulinemia, and chronic graft-versus-host disease.Compare kinase inhibitors.…
BeiGene Announces Results of Phase 3 ASPEN Trial of ...
Dec 16, 2019 · BeiGene Announces Results of Phase 3 ASPEN Trial of Zanubrutinib Compared to Ibrutinib for the Treatment of Patients with Waldenström’s Macroglobulinemia ... and in China, the Company markets ...…
Imbruvica 140 mg hard capsules - Summary of Product ...
Jan 16, 2020 · Ibrutinib was not carcinogenic in a 6-month study in the transgenic (Tg.rasH2) mouse at oral doses up to 2000 mg/kg/day with an exposure margin of approximately 23 (males) to 37 (females) times the human AUC of ibrutinib at a dose of 560 mg daily. Ibrutinib has no genotoxic properties when tested in bacteria, mammalian cells or in mice.95% CI (%): (58.0; 76.1)…
U.S. FDA Approves IMBRUVICA® (ibrutinib) as First Approved ...
Aug 02, 2017 · NORTH CHICAGO, Ill., Aug. 2, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA® (ibrutinib) for the treatment of adult patients with chronic graft-versus-host-disease (cGVHD) after failure of one or more lines of systemic therapy. 1 With this approval, ……